Share

    


In This Section

Home / News & Media / Oncology Newsfeed

Oncology Newsfeed

  • CAP Issues Guideline to Ensure Accurate HPV Testing in Head and Neck Cancers

    The College of American Pathologists (CAP) released its newest evidence-based practice guideline, "Human Papillomavirus (HPV) Testing in Head and Neck Carcinomas," on December 19, 2017.

    The guideline, which recommends accurate assessment of a patient's high-risk HPV status, directly or by surrogate markers, was developed by an interdisciplinary, expert panel that included pathologists, surgeons, radiation oncologists, medical oncologists, patients, and patient advocates.

    Based on a screening of 2,200 peer-reviewed articles and a review of evidence from 492 studies, the panel issued 14 final recommendations in the guideline.

    Learn more on the CAP website.

    Posted 1/3/2018



  • FDA Updates Nilotinib Label to Include Treatment Discontinuation Recommendations for CML with Sustained Molecular Responses

    On December 22, 2017, the U.S. Food and Drug Administration (FDA) updated the product label for nilotinib (Tasigna, Novartis Pharmaceuticals Corp.) to include information on nilotinib discontinuation, post-discontinuation monitoring criteria, and guidance for treatment re-initiation in patients taking nilotinib for Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) who have achieved a sustained molecular response (MR 4.5).

    Patients with newly diagnosed Ph+ CML in the chronic phase (CP) and resistant or intolerant Ph+ CML-CP patients who have achieved a sustained molecular response (MR4.5) may be considered for discontinuation after at least three years of nilotinib. To be considered for discontinuation, patients must have typical BCR-ABL transcripts. An FDA-authorized test with a detection limit below at least MR4.5 must be used to determine discontinuation eligibility. Patients must be frequently monitored by this test to detect possible loss of remission.

    Common adverse reactions in patients who discontinued nilotinib include musculoskeletal symptoms including body aches, bone pain, and extremity pain. Some patients experienced prolonged musculoskeletal symptoms. The long-term outcomes of patients discontinuing versus continuing treatment are unknown at this time.

    Read the FDA announcement.

    Posted 1/2/2018